Dabrafenib (Tafinlar® ) is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.
Rapid Review
| Commenced | Completed | Outcome |
| 11/09/2013 | 02/10/2013 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 03/12/2013 | 24/06/2014 | Reimbursement Recommended |
The NCPE considers dabrafenib (Tafinlar®) to be cost effective compared to vemurafenib.